Immunotherapy in Treating Patients With Resected Liver Metastases From Colon Cancer

Completed · Phase 1/Phase 2

Conditions studied: Colorectal Cancer, Metastatic Cancer

In brief

RATIONALE: Immunotherapy using CEA-treated white blood cells may help a person's body build an immune response to kill their tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of immunotherapy with CEA-treated white blood cells in treating patients with resected liver metastases from colon cancer.

Key facts

Study ID

NCT00003433

Run by

Duke Cancer Institute

Starts

1998-06-01

Expected to finish

2003-08-01

Last updated by the study team

2013-06-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Duke Comprehensive Cancer Center — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.